CZ 48

Drug Profile

CZ 48

Alternative Names: Camptothecin-20-O-Propionate Hydrate; CZ48

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Cao Pharmaceuticals; CHRISTUS Stehlin Foundation for Cancer Research
  • Developer Cao Pharmaceuticals; University of Texas Health Science Center at San Antonio
  • Class Antineoplastics; Camptothecins; Esters; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Lymphoma; Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (PO, Capsule)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease) in USA (PO, Capsule)
  • 11 Apr 2016 CAO Pharma and NMT Pharma initiate enrolment in a phase I trial for Solid tumours in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top